المؤلفون: Yu. K. Toshina, Yu. V. Dinikina, A. S. Egorov, A. Yu. Smirnova, M. B. Belogurova, Ю. К. Тошина, Ю. В. Диникина, А. С. Егоров, А. Ю. Смирнова, М. Б. Белогурова

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 7, № 2 (2020); 115-119 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 7, № 2 (2020); 115-119 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2020-7-2

مصطلحات موضوعية: противоопухолевая терапия, pediatric oncology, neuroblastoma, T-cell lymphoma, secondary neoplasms, anticancer therapy, детская онкология, нейробластома, Т-клеточная лимфома, вторичные опухоли

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/610/557; Federico S.M., Allewelt H.B., Spunt S.L., Hudson M.M., Wu J., Billups C.A., Jenkins J., Santana V.M., Furman W.L., McGregor L.M. Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. J Pediatr Hematol Oncol 2015;37(1):e6–12. doi:10.1097/mph.0000000000000148.; Laverdière C., Liu Q., Yasui Y., Nathan P.C., Gurney J.G., Stovall M., Diller L.R., Cheung N.K., Wolden S., Robison L.L., Sklar C.A. Longterm outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101(16):1131–40. doi:10.1093/jnci/djp230.; Applebaum M.A., Henderson T.O., Lee S.M., Pinto N., Volchenboum S.L., Cohn S.L. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer 2015;62(1):128–33. doi:10.1002/pbc.25249.; Applebaum M.A., Vaksman Z., Lee S.M., Hungate E.A., Henderson T.O., Londone W.B., Pinto N., Volchenboum S.L., Park J.R., Naranjo A., Hero B., Pearson A.D., Stranger B.E., Cohn S.L., Diskin S.J. Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2017;72:177–85. doi:10.1016/j.ejca.2016.11.022.; Rubino C., Adjadj E., Gurerin S., Guibout C., Shamsadin A., Dondon M.-G., Valteau-Couanet D., Hartmann O., Hawkins M., de Vathaire F. Long-term risk of second malignant neoplasm after neuroblastoma in childhood: role of treatment. Int J Cancer 2003;107:791–6. doi:10.1002/ijc.11455.; Kushner B.H., Kramer K., Modak S., Qin L.X., Yataghena K., Jhanwar S.C., Cheung N.K. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer 2009;53:17–22. doi:10.1002/pbc.21931.; Martin A., Schneiderman J., Helenowski I.B., Morgan E., Dilley K., Danner-Koptik K., Hatahet M., Shimada H., Cohn S.L., Kletzel M., Hijiya N. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer 2014;61(8):1350–6. doi:10.1002/pbc.25033.; Garaventa A., Gambini C., Villavecchia G., Cataldo A., Bertolazzi L., Pizzitola M.R., de Bernardi B., Haupt R. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 2002;97(5):1332–8. doi:10.1002/cncr.11167.; Huibregtse K.E., Kieuhoa T.V., Du Bois S.G., Fetzko S., Neuhaus J., Batra V., Maris J.M., Weiss B., Marachelian A., Yanik G.A., Matthay K.K. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine. Eur J Cancer 2016;66:144–52. doi:10.1016/j.ejca.2016.07.017.; Moroz М., Machin D., Faldum A., Hero B., Iehara T., Mosseri V., Ladenstein R., de Bernardi B., Rubie H., Berthold F., Matthay K.K., Monclair T., Ambros P.F., Pearso A.D.J., Cohn S.L., London W.B. Changes over three decades in outcome and the prognostic infl uence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011;47(4):561–71. doi:10.1016/j.ejca.2010.10.022.; Sandoval С., Pui C.H., Bowman L.C., Heaton D., Raimondi S.C., Behm F.G., Head D.R. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol1993;11(6):1039–45. doi:10.1200/JCO.1993.11.6.1039.; Kushner B.H., Cheung N.K., Kramer K., Heller G., Jhanwar S.C. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2016;16(12):3880–9. doi:10.1200/jco.1998.16.12.3880.; Hijiya N., Ness K.K., Ribeiro R.C., Hudson M.M. Acute leukemia as a secondary malignancy in children and adolescents: current fi ndings and issues. Cancer 2016;115(1):23–35. doi:10.1002/cncr.23988.; Barr E., Applebaum M. Genetic predisposition to neuroblastoma. Children 2018;5(9):119. doi:10.3390/children5090119.; https://journal.nodgo.org/jour/article/view/610

الاتاحة: https://journal.nodgo.org/jour/article/view/610
https://doi.org/10.21682/2311-1267-2020-7-2-115-9

المؤلفون: Yu. V. Dinikina, A. Yu. Smirnova, K. M. Golubeva, Yu. E. Chervonok, N. N. Dokhina, A. S. Egorov, M. B. Belogurova, Ю. В. Диникина, А. Ю. Смирнова, К. М. Голубева, Ю. Е. Червонок, Н. Н. Дохина, А. С. Егоров, М. Б. Белогурова

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 5, № 2 (2018); 11-18 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 5, № 2 (2018); 11-18 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2018-5-2

مصطلحات موضوعية: мониторинг, high-dose methotrexate, children, oncology, acute leukemia, central nervous system tumors, lymphoma, leucovorin, toxicity, osteosarcoma, monitoring, высокодозный метотрексат, дети, онкология, острый лейкоз, опухоли центральной нервной системы, лимфома, лейковорин, токсичность, остеосаркома

وصف الملف: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/378/372; Howard S., McCormick J., Pui C. et al. Preventing and managing toxicities of highdose methotrexate. Oncologist 2016;21(12):1471–82. doi:10.1634/theoncologist.2015-0164.; Корман Д.Б. Основы противоопухолевой химиотерапии. М.: Практическая медицина, 2006. 512 с. [Korman D.B. Fundamentals of antitumor chemotherapy. М.: Practicheskaya medicina, 2006. 512 p. (In Russ.)].; Borsi J.D., Schuler D., Moe P.J. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison. Cancer Chemother Pharmacol 1988;22(1):33–5. PMID: 3260832.; Abelson H.T., Fosburg M.T., Beardsley G.P. et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983;1(3):208–16. doi:10.1200/JCO.1983.1.3.208.; Millan N., Pastrana A., Guitter R. et al. Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia. Leuk Res 2018;65:86–93. doi:10.1016/j.leukres.2017.12.010.; Widemann B., Balis F., Kempf-Bielack B. et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004;100(10):2222–32. doi:10.1002/ cncr.20255.; Zhang W., Zhang Q., Zheng T. et al. Delayed high-dose methotrexate excretion and influencing factors in osteosarcoma patients. Chin Med J (Engl) 2016;129(21):2530–4. doi:10.4103/0366-6999.192781.; https://journal.nodgo.org/jour/article/view/378

الاتاحة: https://journal.nodgo.org/jour/article/view/378
https://doi.org/10.17650/2311-1267-2018-5-2-11-18